CI
CRSP icon

Corient IA’s CRISPR Therapeutics CRSP Stock Holding History

Corient IA’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$139K Sell
2,540
-1,000
-28% -$52.7K 0.13% 200
2026
Q1 		$168K Sell
3,540
-460
-12% -$24.3K 0.16% 227
2025
Q4 		$210K Hold
4,000
– – 0.2% 198
2025
Q3 		$259K Sell
4,000
-1,000
-20% -$57.4K 0.19% 201
2025
Q2 		$243K Buy
+5,000
New +$193K 0.14% 255

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Corient IA's CRSP Position: Q2 2026 in Review

Corient IA reduced its CRISPR Therapeutics (CRSP) stake by 28% in Q2 2026, selling an estimated $52.7K and leaving 2,540 shares worth $139K. The position accounts for 0.13% of the portfolio, ranked #200.

Corient IA first reported a position in CRSP in Q2 2025 and has held it in 5 quarters since. The position peaked at $259K in Q3 2025. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Corient IA held 2,540 shares of CRISPR Therapeutics worth $139K as of Q2 2026.
  • Corient IA sold 1,000 CRISPR Therapeutics shares in Q2 2026, an estimated $52.7K.
  • CRISPR Therapeutics made up 0.13% of Corient IA's portfolio in Q2 2026, its #200 holding.
  • Corient IA first reported a position in CRISPR Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Corient IA's CRISPR Therapeutics position peaked at $259K in Q3 2025.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Corient IA's 13F filing for Q2 2026, filed 12 Aug 2026.